Aripiprazole and risperidone in the treatment of schizophrenia-control study

Objective:To compare aripiprazole and risperidone in the treatment of schizophrenia and safety.Methods:58 cases of pain in patients with schizophrenia were randomly divided into two groups of 29 cases,8 weeks.Before treatment and at 2 weeks,4 weeks,8 weeks patients using positive and negative symptoms and side effects rating scale scale clinical efficacy and adverse reactions.Results: After treatment,the Positive and Negative Syndrome Scale total score and factor scores than those before treatment significantly decreased(P0.05 or P0.01),that the score difference between the two groups are of utmost significant(P0.05);treatment 8 weeks,aripiprazole group was 75.87% efficiency,efficiency 89.66%,risperidone group were 75.86%,93.10%,the difference was not significant(P0.05).Two sets of adverse reactions were mild,but the aripiprazole group akathisia,weight gain and menstrual disorders / lactation were significantly lower than the risperidone group(P0.05).While the dry mouth incidence was significantly higher(P0.05).Conclusions: Aripiprazole and risperidone in the treatment of schizophrenia,clinicalefficacy and safety of certain similarities and differences,the clinical drug of choice based on individual differences.